ASCO Alert | | | Thursday, May 28, 2020 In mid-April, at the recommendation of an Independent Data Monitoring Committee, AstraZeneca unblinded a phase 3 trial of Tagrisso two years early. And now, the public is getting a look at what prompted the move: Results from a study investigators are calling “a home run.” |
|
|---|
|
| | | Thursday, May 28, 2020 In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data in post-chemo patients. In a phase 3 study, Bavencio extended patients’ lives by a median 21.4 months, compared with 14.3 months for best supportive care. |
|
|---|
|
|
|
